EBOS Group
- Home ›
- NZ ›
- Healthcare
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia and New Zealand. The last earnings update was 60 days ago. More info.
Add to Portfolio Compare Print
EBO Share Price and Events
7 Day Returns
1 Year Returns
EBO Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| EBOS Group (EBO) | 2.8% | 2.6% | 3.6% | 22.7% | 35% | 145.2% |
| NZ Healthcare | 3.8% | 1.8% | 3% | 9.1% | 28.1% | 63.2% |
| NZ Market | 1.4% | 4.5% | 6.6% | 12.3% | 23.9% | 48% |
1 Year Return vs Industry and Market
- EBO outperformed the Healthcare industry which returned 9.1% over the past year.
- EBO outperformed the Market in New Zealand which returned 12.3% over the past year.
EBO Value
Is EBOS Group undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
EBOS Group
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for EBOS Group.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 6 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.6% |
| Perpetual Growth Rate | 10-Year NZ Government Bond Rate | 2.4% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year NZ Govt Bond Rate | 2.4% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.71 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.711 (1 + (1- 30%) (22.78%)) |
0.883 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.88 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.37% + (0.883 * 5.96%) |
7.63% |
Discounted Cash Flow Calculation for NZSE:EBO using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for EBOS Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (AUD, Millions) | Source |
Present Value Discounted (@ 7.63%) |
|
|---|---|---|---|
| 2019 | 66.45 | Analyst x2 | 61.74 |
| 2020 | 201.82 | Analyst x2 | 174.22 |
| 2021 | 176.75 | Analyst x1 | 141.77 |
| 2022 | 161.61 | Est @ -8.57% | 120.43 |
| 2023 | 153.07 | Est @ -5.29% | 105.98 |
| 2024 | 148.50 | Est @ -2.99% | 95.53 |
| 2025 | 146.45 | Est @ -1.38% | 87.53 |
| 2026 | 146.07 | Est @ -0.26% | 81.12 |
| 2027 | 146.85 | Est @ 0.53% | 75.77 |
| 2028 | 148.44 | Est @ 1.08% | 71.16 |
| Present value of next 10 years cash flows | A$1,015.24 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= A$148.44 × (1 + 2.37%) ÷ (7.63% – 2.37%) |
A$2,889.02 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= A$2,889.02 ÷ (1 + 7.63%)10 |
A$1,384.92 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= A$1,015.24 + A$1,384.92 |
A$2,400.16 |
| Equity Value per Share (AUD) |
= Total value / Shares Outstanding
= A$2,400.16 / 151.60 |
A$15.83 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | AUD/NZD
(Reporting currency to currency of NZSE:EBO) |
1.069 |
| Value per Share (NZD) |
= Value per Share in AUD x Exchange Rate (AUD/NZD)
= A$15.83 x 1.069 |
NZ$16.92 |
| Value per share (NZD) | From above. | NZ$16.92 |
| Current discount | Discount to share price of
NZ$21.90
= -1 x (NZ$21.90 - NZ$16.92) / NZ$16.92 |
-29.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of EBOS Group is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for EBOS Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
EBOS Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$0.92 |
| NZSE:EBO Share Price ** | NZSE (2019-04-18) in NZD | NZ$21.9 |
| NZSE:EBO Share Price converted to AUD reporting currency | Exchange rate (NZD/ AUD) 0.936 | A$20.49 |
| New Zealand Healthcare Industry PE Ratio | Median Figure of 7 Publicly-Listed Healthcare Companies | 11x |
| New Zealand Market PE Ratio | Median Figure of 90 Publicly-Listed Companies | 17.72x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of EBOS Group.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NZSE:EBO Share Price ÷ EPS (both in AUD) = 20.49 ÷ 0.92 |
22.31x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- EBOS Group is overvalued based on earnings compared to the NZ Healthcare industry average.
- EBOS Group is overvalued based on earnings compared to the New Zealand market.
Price based on expected Growth
Does
EBOS Group's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 22.31x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts |
10.1%per year |
| New Zealand Healthcare Industry PEG Ratio | Median Figure of 7 Publicly-Listed Healthcare Companies | 0.99x |
| New Zealand Market PEG Ratio | Median Figure of 66 Publicly-Listed Companies | 1.5x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 22.31x ÷ 10.1% |
2.2x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- EBOS Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
EBOS Group's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$6.93 |
| NZSE:EBO Share Price * | NZSE (2019-04-18) in NZD | NZ$21.9 |
| NZSE:EBO Share Price converted to AUD reporting currency | Exchange rate (NZD/ AUD) 0.936 | A$20.49 |
| New Zealand Healthcare Industry PB Ratio | Median Figure of 7 Publicly-Listed Healthcare Companies | 1.17x |
| New Zealand Market PB Ratio | Median Figure of 126 Publicly-Listed Companies | 1.55x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NZSE:EBO Share Price ÷ Book Value per Share (both in AUD) = 20.49 ÷ 6.93 |
2.96x |
* Primary Listing of EBOS Group.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- EBOS Group is overvalued based on assets compared to the NZ Healthcare industry average.
Value checks
We assess EBOS Group's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) EBOS Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
EBO Future Performance
How is EBOS Group expected to perform in the next 1 to 3 years based on estimates from 6 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- EBOS Group's earnings growth is expected to exceed the low risk savings rate of 2.4%.
Growth vs Market Checks
- EBOS Group's earnings growth is expected to exceed the New Zealand market average.
- EBOS Group's revenue growth is expected to exceed the New Zealand market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NZSE:EBO Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts | 10.1% |
| NZSE:EBO Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts | 7.3% |
| New Zealand Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 9.8% |
| New Zealand Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 10.2% |
| New Zealand Market Earnings Growth Rate | Market Cap Weighted Average | 6.1% |
| New Zealand Market Revenue Growth Rate | Market Cap Weighted Average | 5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 9,315 | 210 | 1 | |
| 2022-06-30 | 8,953 | 195 | 1 | |
| 2021-06-30 | 8,592 | 192 | 178 | 5 |
| 2020-06-30 | 8,303 | 251 | 165 | 6 |
| 2019-06-30 | 7,060 | 133 | 140 | 6 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 7,147 | 116 | 140 |
| 2018-09-30 | 6,926 | 136 | 136 |
| 2018-06-30 | 6,971 | 161 | 137 |
| 2018-03-31 | 7,161 | 176 | 137 |
| 2017-12-31 | 6,927 | 179 | 129 |
| 2017-09-30 | 6,998 | 157 | 126 |
| 2017-06-30 | 7,276 | 137 | 127 |
| 2017-03-31 | 7,011 | 169 | 121 |
| 2016-12-31 | 7,397 | 217 | 127 |
| 2016-09-30 | 7,032 | 214 | 123 |
| 2016-06-30 | 6,797 | 215 | 122 |
| 2016-03-31 | 6,057 | 169 | 110 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
All data from EBOS Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | ||||
| 2022-06-30 | ||||
| 2021-06-30 | 1.19 | 1.21 | 1.16 | 4.00 |
| 2020-06-30 | 1.10 | 1.15 | 1.07 | 5.00 |
| 2019-06-30 | 0.91 | 0.95 | 0.88 | 5.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | 0.92 |
| 2018-09-30 | 0.89 |
| 2018-06-30 | 0.90 |
| 2018-03-31 | 0.90 |
| 2017-12-31 | 0.85 |
| 2017-09-30 | 0.83 |
| 2017-06-30 | 0.84 |
| 2017-03-31 | 0.80 |
| 2016-12-31 | 0.84 |
| 2016-09-30 | 0.81 |
| 2016-06-30 | 0.80 |
| 2016-03-31 | 0.73 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess EBOS Group's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the New Zealand market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the New Zealand market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
EBOS Group has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
EBO Past Performance
How has EBOS Group performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- EBOS Group's year on year earnings growth rate has been positive over the past 5 years.
- EBOS Group's 1-year earnings growth is less than its 5-year average (8.6% vs 13%)
- EBOS Group's earnings growth has exceeded the NZ Healthcare industry average in the past year (8.6% vs -4.6%).
Earnings and Revenue History
All data from EBOS Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 7,147.12 | 139.57 | 346.62 | |
| 2018-09-30 | 6,925.95 | 135.68 | 331.59 | |
| 2018-06-30 | 6,971.15 | 137.02 | 329.13 | |
| 2018-03-31 | 7,161.22 | 136.81 | 327.38 | |
| 2017-12-31 | 6,926.75 | 128.51 | 306.32 | |
| 2017-09-30 | 6,998.26 | 126.04 | 291.76 | |
| 2017-06-30 | 7,275.77 | 127.16 | 285.12 | |
| 2017-03-31 | 7,010.75 | 121.32 | 265.18 | |
| 2016-12-31 | 7,397.34 | 126.74 | 269.79 | |
| 2016-09-30 | 7,032.16 | 123.02 | 259.98 | |
| 2016-06-30 | 6,796.65 | 121.55 | 254.94 | |
| 2016-03-31 | 6,057.36 | 109.68 | 231.76 | |
| 2015-12-31 | 5,957.04 | 109.35 | 232.94 | |
| 2015-09-30 | 5,640.85 | 101.07 | 221.42 | |
| 2015-06-30 | 5,342.75 | 93.28 | 210.55 | |
| 2015-03-31 | 5,868.28 | 99.51 | 233.46 | |
| 2014-12-31 | 5,607.70 | 92.18 | 225.26 | |
| 2014-09-30 | 5,182.46 | 84.05 | 209.23 | |
| 2014-06-30 | 5,344.90 | 85.48 | 216.89 | |
| 2014-03-31 | 4,597.98 | 72.41 | 186.84 | |
| 2013-12-31 | 3,746.33 | 57.70 | 152.53 | |
| 2013-09-30 | 2,623.15 | 40.46 | 113.10 | |
| 2013-06-30 | 1,540.78 | 23.84 | 74.69 | |
| 2013-03-31 | 1,332.57 | 23.92 | 67.57 | |
| 2012-12-31 | 1,187.66 | 24.92 | 63.46 | |
| 2012-09-30 | 1,166.91 | 23.67 | 59.19 | |
| 2012-06-30 | 1,120.50 | 21.92 | 53.66 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- EBOS Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- EBOS Group used its assets more efficiently than the NZ Healthcare industry average last year based on Return on Assets.
- EBOS Group has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess EBOS Group's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
EBOS Group has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
EBO Health
How is EBOS Group's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up EBOS Group's finances.
The net worth of a company is the difference between its assets and liabilities.
- EBOS Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- EBOS Group's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from EBOS Group Company Filings, last reported 3 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 1,051.38 | 707.59 | 152.14 |
| 2018-09-30 | 1,051.38 | 707.59 | 152.14 |
| 2018-06-30 | 1,114.19 | 583.15 | 149.58 |
| 2018-03-31 | 1,144.66 | 599.09 | 153.67 |
| 2017-12-31 | 1,084.61 | 538.40 | 129.86 |
| 2017-09-30 | 1,099.30 | 545.69 | 131.62 |
| 2017-06-30 | 1,099.49 | 571.93 | 154.74 |
| 2017-03-31 | 1,055.57 | 549.08 | 148.55 |
| 2016-12-31 | 1,086.76 | 450.46 | 169.17 |
| 2016-09-30 | 1,073.67 | 445.03 | 167.13 |
| 2016-06-30 | 1,040.61 | 358.91 | 115.09 |
| 2016-03-31 | 980.84 | 338.29 | 108.48 |
| 2015-12-31 | 1,007.51 | 471.27 | 109.02 |
| 2015-09-30 | 974.04 | 455.61 | 105.40 |
| 2015-06-30 | 925.40 | 380.79 | 96.43 |
| 2015-03-31 | 1,032.68 | 424.94 | 107.61 |
| 2014-12-31 | 956.35 | 421.20 | 65.68 |
| 2014-09-30 | 892.93 | 393.27 | 61.33 |
| 2014-06-30 | 908.92 | 378.26 | 83.59 |
| 2014-03-31 | 916.34 | 381.35 | 84.27 |
| 2013-12-31 | 885.14 | 409.27 | 85.26 |
| 2013-09-30 | 855.93 | 395.76 | 82.45 |
| 2013-06-30 | 257.66 | 316.40 | 168.00 |
| 2013-03-31 | 244.98 | 300.84 | 159.73 |
| 2012-12-31 | 171.68 | 110.20 | 33.22 |
| 2012-09-30 | 172.43 | 110.68 | 33.37 |
| 2012-06-30 | 163.60 | 111.51 | 41.29 |
- EBOS Group's level of debt (67.3%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (46.2% vs 67.3% today).
- Debt is not well covered by operating cash flow (16.4%, less than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 9.4x coverage).
Financial health checks
We assess EBOS Group's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) EBOS Group has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
EBO Dividends
What is EBOS Group's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
NZ$2,000 of
EBOS Group
shares you are expected to receive
NZ$64
in your first year as a dividend.
Dividend Amount
- EBOS Group's pays a lower dividend yield than the bottom 25% of dividend payers in New Zealand (3.23%).
- EBOS Group's dividend is below the markets top 25% of dividend payers in New Zealand (5.65%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| New Zealand Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 7 Stocks | 2.5% |
| New Zealand Market Average Dividend Yield | Market Cap Weighted Average of 75 Stocks | 3.8% |
| New Zealand Minimum Threshold Dividend Yield | 10th Percentile | 1.9% |
| New Zealand Bottom 25% Dividend Yield | 25th Percentile | 3.2% |
| New Zealand Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | ||
| 2022-06-30 | ||
| 2021-06-30 | 0.81 | 5.00 |
| 2020-06-30 | 0.75 | 6.00 |
| 2019-06-30 | 0.65 | 6.00 |
| Date (Data in A$) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-19 | 0.654 | 3.267 |
| 2018-10-10 | 0.647 | 3.358 |
| 2018-02-20 | 0.591 | 3.417 |
| 2017-08-24 | 0.559 | 3.551 |
| 2017-08-23 | 0.576 | 3.540 |
| 2017-04-05 | 0.571 | 3.513 |
| 2016-10-12 | 0.591 | 3.766 |
| 2016-03-30 | 0.462 | 3.088 |
| 2015-10-13 | 0.442 | 3.502 |
| 2015-02-24 | 0.387 | 4.159 |
| 2014-08-26 | 0.363 | 4.357 |
| 2014-02-20 | 0.317 | 3.633 |
| 2013-10-18 | 0.276 | 3.371 |
| 2013-02-21 | 0.290 | 3.837 |
| 2012-09-10 | 0.256 | 4.051 |
| 2012-02-21 | 0.232 | 4.182 |
| 2011-08-26 | 0.229 | 4.759 |
| 2010-08-26 | 0.217 | 4.314 |
| 2009-08-20 | 0.182 | 4.103 |
| 2009-04-22 | 0.000 | 0.000 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dividends per share have been stable in the past 10 years.
- Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of
EBOS Group's earnings are
paid
to the shareholders as a dividend.
- Dividends paid are covered by earnings (1.4x coverage).
- Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
Income/ dividend checks
We assess EBOS Group's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can EBOS Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) EBOS Group has a total score of 4/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
EBO Management
CEO
| COMPENSATION | A$1,252,776 |
| TENURE AS CEO | 1 years |
CEO Bio
Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity served as the Chief Financial Officer of EBOS Group Limited from July 1, 2014 to March 31, 2018 and served as its Company Secretary until March 31, 2018. Mr. Cullity has more than 25 years’ experience in senior management roles within publicly listed companies in Australia and the United States. He has worked on a number of corporate transactions involving acquisitions, business divestments and debt refinancing. Mr. Cullity served as the Chief Financial Officer of Sigma Pharmaceuticals Ltd., until August 31, 2007. He has more than 25 years’ experience in senior management roles within publicly listed companies in Australia and the United States. He holds a Bachelor of Economics from Monash University and is a member of Chartered Accountants Australia and New Zealand.
CEO Compensation
- Insufficient data for John to compare compensation growth.
- John's remuneration is lower than average for companies of similar size in New Zealand.
Management Team Tenure
Average tenure of the EBOS Group management team in years:
- The tenure for the EBOS Group management team is about average.
Management Team
John Cullity
Chief Executive Officer
A$1M
1 yrs
Shaun Hughes
Chief Financial Officer
0.8 yrs
Simon Bunde
Executive General Manager of Operations & Supply Chain
Andrea Bell
Chief Information Officer
4.3 yrs
Mark Connell
Manager of Investor Relations
Janelle Cain
General Counsel
4.3 yrs
Tim Goldenberg
Chief Human Resources Officer
1 yrs
Sean Duggan
Chief Executive Officer of Animal Care & Consumer Brands
4.8 yrs
Brett Barons
Chief Executive Officer of Symbion
1.3 yrs
Stuart Spencer
Executive General Manager of Pharmacy & Institutional Healthcare
2.8 yrs
Board of Directors Tenure
Average tenure and age of the EBOS Group board of directors in years:
- The tenure for the EBOS Group board of directors is about average.
Board of Directors
Mark Waller
Independent Chairman of the Board
64
3.5 yrs
Liz Coutts
Independent Director
59
15.8 yrs
Sarah Ottrey
Independent Director
53
12.6 yrs
Stuart McGregor
Director
5.8 yrs
Peter Williams
Director
5.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (NZ$) | Value (NZ$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 25. Mar 19 | Sell | Mark Waller | Individual | 20. Mar 19 | 22. Mar 19 | -35,000 | NZ$21.61 | NZ$-756,472 | ||
Management checks
We assess EBOS Group's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) EBOS Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
EBO News
Simply Wall St News
What Should You Know About EBOS Group Limited's (NZSE:EBO) Future?
Looking at EBOS Group Limited's (NZSE:EBO) earnings update in December 2018,. … with earnings expected to grow by 9.4% in the upcoming year … the higher past 5-year average growth rate of 13%
Simply Wall St - – Full articleWhat You Should Know About EBOS Group Limited's (NZSE:EBO) Financial Strength
While small-cap stocks, such as EBOS Group Limited (NZSE:EBO) with its market cap of NZ$3.2b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Understanding the company's financial health becomes. … The following basic checks can help you get a picture of the company's balance sheet strength.
Simply Wall St - – Full articleIs EBOS Group Limited (NZSE:EBO) An Attractive Dividend Stock?
Historically, EBOS Group Limited (NZSE:EBO) has been paying a dividend to shareholders. … Let's take a look at EBOS Group in more detail. … Check out our latest analysis for EBOS Group
Simply Wall St - – Full articleHave Investors Priced In EBOS Group Limited's (NZSE:EBO) Growth?
Looking at EBOS Group Limited’s (NZSE:EBO) fundamentals some investors are wondering if its last closing price of NZ$21.35 represents a good value for money for this high growth stock. … Check out our latest analysis for EBOS Group? … According to the analysts covering the company, the following few years should bring about good growth prospects for EBOS Group
Simply Wall St - – Full articleAnnouncing: EBOS Group (NZSE:EBO) Stock Increased An Energizing 110% In The Last Five Years
But on a lighter note, a good company can see its share price rise well over 100%. … During five years of share price growth, EBOS Group achieved compound earnings per share (EPS) growth of 10% per year. … It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years
Simply Wall St - – Full articleHow Did EBOS Group Limited's (NZSE:EBO) 13% ROE Fare Against The Industry?
Our data shows EBOS Group has a return on equity of 13% for the last year. … That means that for every NZ$1 worth of shareholders' equity, it generated NZ$0.13 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs EBOS Group Limited's (NZSE:EBO) Balance Sheet Strong Enough To Weather A Storm?
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as EBOS Group Limited (NZSE:EBO) with a market-capitalization of NZ$3.3b, rarely draw their attention. … This article will examine EBO’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … See our latest analysis for EBOS Group
Simply Wall St - – Full articleWhat Do Analysts Think About EBOS Group Limited's (NZSE:EBO) Growth?
Help shape the future of investing tools and you could win a $250 gift card! … The latest earnings update EBOS Group Limited (NZSE:EBO) released in June 2018a
Simply Wall St - – Full articleStocks Take A Hit: How Will EBOS Group Limited (NZSE:EBO) Fare?
I'm talking about the well-proven, robust track record EBOS Group Limited. … See our latest analysis for EBOS Group. … EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia and New Zealand
Simply Wall St - – Full articleDespite Its High P/E Ratio, Is EBOS Group Limited (NZSE:EBO) Still Undervalued?
To keep it practical, we'll show how EBOS Group Limited's (NZSE:EBO) P/E ratio could help you assess the value on offer. … EBOS Group has a price to earnings ratio of 21.34, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleEBO Company Info
Description
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company offers health logistics; loyalty, generics, compliance, business intelligence, and store software services for pharmacy industry; pharmacy management software; medication management solutions; and branding and signage solutions, marketing and promotions, ticketing program, individual store layouts and planograms, loyalty membership, and store performance benchmarking tools to pharmacies, as well as markets and sells health and personal care products. It is also involved in the logistics and distribution of daily medical consumables, surgical solutions, and medical and healthcare equipment; provision of healthcare supply chain solutions; wholesale and distribution of products to public and private hospitals, day surgeries, government, and non-profit health agencies; production of educational materials, web sites, disease awareness, and professional development programs; and outsourced pharmacy services to hospitals. In addition, the company offers healthcare distribution, warehousing, clinical trial management, and product registration services; contract logistics services, such as inventory management, warehousing, and distribution of healthcare products; and clinical trial logistics. Further, it engages in the marketing and distribution of premium food for dogs and cats, and fish tanks; wholesale of veterinary products for companion animals, production animals, and equine world; and specialty pet retail, supermarkets, and pet food retail activities. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was founded in 1922 and is headquartered in Docklands, Australia.
Details
| Name: | EBOS Group Limited |
| EBO | |
| Exchange: | NZSE |
| Founded: | 1922 |
| NZ$3,320,037,196 | |
| 151,599,872 | |
| Website: | http://www.ebosgroup.com |
| Address: |
EBOS Group Limited 737 Bourke Street, Level 7, Docklands, Victoria, 3008, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NZSE | EBO | Ordinary Shares | New Zealand Stock Exchange | NZ | NZD | 21. Jun 1999 | |
| ASX | EBO | Ordinary Shares | Australian Securities Exchange | AU | AUD | 21. Jun 1999 | |
| CHIA | EBO | Ordinary Shares | Chi-X Australia | AU | AUD | 21. Jun 1999 |
Number of employees
Current staff
Industry
| Health Care Distributors | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/21 10:33 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/02/24 |
| Last earnings filing: | 2019/02/20 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
